Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...

CHATHAM, NJ / ACCESS Newswire / March 31, 2025 / This post was written and published as a collaboration between the in-house ...

Vertex Pharmaceuticals reported revenues of $2.91 billion ... develops messenger RNA (mRNA) medicines that direct the body's ...

The innovative treatment, provided by Abu Dhabi Stem Cells Center (ADSCC), in coordination with DoH and in collaboration with ...

We have two types of hair, says dermatologist Elizabeth Houshmand. Vellus hairs, or “peach fuzz,” cover virtually our entire ...

Vertex's cloud growth momentum remains strong, with a 27% y/y increase in 4Q24. Read more to see why I upgrade VERX stock ...

Leading Chinese module manufacturer Trinasolar has developed an 808W solar module that uses perovskite/silicon tandem solar ...

The Department of Health - Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, has announced the ...

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...